HZNP News and Press, Horizon Therapeutics Public Limited Company From 01/22/23

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Mid Cap Strategy applies quantitative and funda...

Horizon Therapeutics ( NASDAQ: HZNP ) announced Wednesday that dazodalibep, a candidate for autoimmune disease Sjögren’s syndrome, met the primary endpoint for the second population in a Phase 2 trial. In September, the company said that dazodalibep also met the primary en...

- Trial also met primary endpoint in first study population as announced September 2022 – - The Company plans to work with the FDA to design a Phase 3 program to begin in 2023, ahead of expectations - Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the ...

NEW YORK, NY / ACCESSWIRE / January 15, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: KnowBe4, Inc. (NASDAQ:KNBE)'s sale ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 202...

Summary We conclude our roundtable series with Biotech and Healthcare coverage. Three of our Marketplace contributors give their analysis and shared one top idea. Look for more roundtables and analysis this summer from our community of 180-plus Marketplace services. ~ By...

Summary The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights. This article will discuss the 10 largest biotech companies (by ma...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof. ...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...